Hemogenyx Pharmaceuticals (LON:HEMO) Trading 3.3% Higher – Still a Buy?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price traded up 3.3% during mid-day trading on Thursday . The company traded as high as GBX 790.45 and last traded at GBX 790. 19,094 shares traded hands during trading, a decline of 33% from the average session volume of 28,465 shares. The stock had previously closed at GBX 764.50.

Hemogenyx Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38. The company has a market capitalization of £53.72 million, a P/E ratio of -4.63 and a beta of 1.50. The business has a 50 day moving average of GBX 775.45 and a 200-day moving average of GBX 788.95.

Hemogenyx Pharmaceuticals (LON:HEMO) last announced its earnings results on Thursday, April 30th. The company reported GBX (170.60) earnings per share for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.